AIM: This study aimed to compare the efficacy and safety between standard and low-dose tirofiban in the treatment of elderly high-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients who underwent percutaneous coronary intervention (PCI). METHODS:Ninety-four very elderly (>or=80 years) high-risk patients with NSTE-ACS were randomly assigned to the standard or the low-dose group. Upstream tirofiban was administered intravenously with a bolus dose of 0.4 microg x kg(-1) x min(-1) over a period of 30 min after the diagnosis had been confirmed, and was followed by a 36-48 h infusion of 0.10 microg x kg(-1) x min(-1) or 0.075 microg x kg(-1) x min(-1). PCI was performed within 24 h of admission. Platelet aggregation inhibition and thrombolysis in myocardial infarction (TIMI) grade flow were assessed. The major adverse cardiac events (MACEs), including death, myocardial infarction, recurrent angina and urgent target-vessel revascularization (TVR), were documented at 7 d, 30 d, and 6 months, and bleeding events were recorded at 7 d. RESULTS: Although a significantly higher inhibition of platelet aggregation was observed in the standard-dose group (P<0.05), angiographic PCI success was similar between the two groups (P>0.05). The rate of MACEs was not significantly different at 7 days (2.1% vs 4.4%, P=0.61), 30 days (6.3% vs 8.7%, P=0.71) and 6 months (14.6% vs 17.4%, P=0.71). Major bleeding events were significantly higher in the standard-dose group (10.4% vs 0.0%, P=0.03). CONCLUSION: In very elderly high-risk patients with NSTE-ACS undergoing PCI, low-dosetirofiban offered about the same level of protection from major ischemic events that standard doses did, with less associated bleeding.
RCT Entities:
AIM: This study aimed to compare the efficacy and safety between standard and low-dose tirofiban in the treatment of elderly high-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients who underwent percutaneous coronary intervention (PCI). METHODS: Ninety-four very elderly (>or=80 years) high-risk patients with NSTE-ACS were randomly assigned to the standard or the low-dose group. Upstream tirofiban was administered intravenously with a bolus dose of 0.4 microg x kg(-1) x min(-1) over a period of 30 min after the diagnosis had been confirmed, and was followed by a 36-48 h infusion of 0.10 microg x kg(-1) x min(-1) or 0.075 microg x kg(-1) x min(-1). PCI was performed within 24 h of admission. Platelet aggregation inhibition and thrombolysis in myocardial infarction (TIMI) grade flow were assessed. The major adverse cardiac events (MACEs), including death, myocardial infarction, recurrent angina and urgent target-vessel revascularization (TVR), were documented at 7 d, 30 d, and 6 months, and bleeding events were recorded at 7 d. RESULTS: Although a significantly higher inhibition of platelet aggregation was observed in the standard-dose group (P<0.05), angiographic PCI success was similar between the two groups (P>0.05). The rate of MACEs was not significantly different at 7 days (2.1% vs 4.4%, P=0.61), 30 days (6.3% vs 8.7%, P=0.71) and 6 months (14.6% vs 17.4%, P=0.71). Major bleeding events were significantly higher in the standard-dose group (10.4% vs 0.0%, P=0.03). CONCLUSION: In very elderly high-risk patients with NSTE-ACS undergoing PCI, low-dose tirofiban offered about the same level of protection from major ischemic events that standard doses did, with less associated bleeding.
Authors: C P Cannon; W S Weintraub; L A Demopoulos; R Vicari; M J Frey; N Lakkis; F J Neumann; D H Robertson; P T DeLucca; P M DiBattiste; C M Gibson; E Braunwald Journal: N Engl J Med Date: 2001-06-21 Impact factor: 91.245
Authors: Alvaro Avezum; Marcia Makdisse; Frederick Spencer; Joel M Gore; Keith A A Fox; Gilles Montalescot; Kim A Eagle; Kami White; Rajendra H Mehta; Elias Knobel; Jean-Philippe Collet Journal: Am Heart J Date: 2005-01 Impact factor: 4.749
Authors: Karen P Alexander; Matthew T Roe; Anita Y Chen; Barbara L Lytle; Charles V Pollack; Joanne M Foody; William E Boden; Sidney C Smith; W Brian Gibler; E Magnus Ohman; Eric D Peterson Journal: J Am Coll Cardiol Date: 2005-09-29 Impact factor: 24.094
Authors: Robert A Harrington; Richard C Becker; Christopher P Cannon; David Gutterman; A Michael Lincoff; Jeffrey J Popma; Gabriel Steg; Gordon H Guyatt; Shaun G Goodman Journal: Chest Date: 2008-06 Impact factor: 9.410
Authors: Richard G Bach; Christopher P Cannon; William S Weintraub; Peter M DiBattiste; Laura A Demopoulos; H Vernon Anderson; Paul T DeLucca; Elizabeth M Mahoney; Sabina A Murphy; Eugene Braunwald Journal: Ann Intern Med Date: 2004-08-03 Impact factor: 25.391
Authors: A K Rao; C Pratt; A Berke; A Jaffe; I Ockene; T L Schreiber; W R Bell; G Knatterud; T L Robertson; M L Terrin Journal: J Am Coll Cardiol Date: 1988-01 Impact factor: 24.094
Authors: Omer Celal Elcioglu; Abdullah Ozkok; Timur Selcuk Akpınar; Fatih Tufan; Murat Sezer; Sabahattin Umman; Sevgi Kalayoglu Besısık Journal: Int J Hematol Date: 2012-07-06 Impact factor: 2.490